Prosecution Insights
Last updated: October 02, 2026
Application No. 18/979,814

Methods And Kits For Assessing Central Nervous System Integrity

Non-Final OA §DP
Filed
Dec 13, 2024
Priority
Mar 26, 2012 — provisional 61/615,463 +5 more
Examiner
CERIONI, DANIEL LEE
Art Unit
Tech Center
Assignee
The United States Government as represented by the Department of Veterans Affairs
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
502 granted / 778 resolved
+4.5% vs TC avg
Strong +28% interview lift
Without
With
+28.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
69 currently pending
Career history
849
Total Applications
across all art units

Statute-Specific Performance

§101
9.9%
-30.1% vs TC avg
§103
42.9%
+2.9% vs TC avg
§102
12.7%
-27.3% vs TC avg
§112
32.3%
-7.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 778 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim(s) 1-2 of U.S. Patent No. 12,291,361 to Samadani et al. (hereinafter “Samadani”). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the instant application are broader than Samadani. Allowable Subject Matter Claim(s) 1-7 would be allowable if rewritten, amended, or a terminal disclaimer filed to overcome the double patenting rejection, set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: U.S. Patent Application Publication No. 2010/0238405 to Newman et al. (hereinafter “Newman”) discloses a system (Abstract) comprising: a display (130) (Fig. 2) (para [0092]) configured to present a stimulus to the subject (para [0092]); an eye tracker (120) (Fig. 2) (para [0090]) having a camera (para [0120]), the eye tracker being configured and arranged to track an eye movement of a subject (para [0120]) along a trajectory having a perimeter to obtain at least 100,000 samples of eye position (para [0090] and [0097]) over a period of 30 to 500 seconds (para [0010], [0054], and/or [0164]); the eye movement being tracked in response to a visual stimulus presented on the display (para [0092]); a processor (112) (Fig. 2) (para [0089]) in communication with the eye tracker (as can be seen in Fig. 2), the processor being configured and arranged to: create a dataset of the eye movement (para [0098]). U.S. Patent Application Publication No. 2010/0100001 to Aguilar et al. (hereinafter “Aguilar”) teaches generate a plot of a dataset (Fig. 4), the plot reflecting a timecourse of eye position versus time (Fig. 4). U.S. Patent Application Publication No. 2002/0169364 to Baumzweiger et al. (hereinafter “Baumzweiger”) teaches identifying one or more features to indicate a deficit in cranial nerve function (para [0047]-[0048]). However, the prior art of record does not disclose and would not have rendered obvious the ordered combination of elements recited in the claim(s). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL LEE CERIONI whose telephone number is (313) 446-4818. The examiner can normally be reached M - F 8:00 AM - 5:00 PM PT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached at (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANIEL L CERIONI/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Dec 13, 2024
Application Filed
Jul 29, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12745925
GAIT INFORMATION GENERATION DEVICE, GAIT MEASUREMENT SYSTEM, GAIT INFORMATION GENERATION METHOD, AND RECORDING MEDIUM
2y 6m to grant Granted Sep 29, 2026
Patent 12734335
STEERABLE GUIDE WIRE AND CATHETER WITH SHAPE CHANGE IN-SITU
5y 5m to grant Granted Sep 15, 2026
Patent 12733870
METHOD OF MEASUREMENT OF KNEE STRENGTH CHARACTERISTICS IN PARTICULAR IN ISOKINETIC MOVEMENT AND DEVICE FOR CARRYING OUT THIS METHOD
4y 5m to grant Granted Sep 15, 2026
Patent 12721557
OVERMOLDED HEMOLYSIS-REDUCTION ACCESSORIES FOR DIRECT BLOOD DRAW
3y 5m to grant Granted Sep 01, 2026
Patent 12721976
GUIDEWIRE DEVICES HAVING SHAPEABLE TIPS AND BYPASS CUTS
2y 6m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+28.0%)
3y 6m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 778 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month